Szelenyi I
Pharmazie. 2014 Jun;69(6):414-6.
Allergic rhinitis (AR) results from a complex allergen-driven mucosal inflammation in the nasal cavity. Current guideline-based therapy for allergic rhinitis include oral and nasal antihistamines, topical and systemic glucocorticoids, decongestants, antimuscarinic agents, mast cell stabilizing drugs, leukotriene-receptor antagonists, and others. In spite of guideline recommendations, most patients are using multiple therapies in an attempt to achieve symptom control. Therefore, more effective therapies for the management of AR are clearly required. Recently, a novel fixed dose combination containing azelastine and fluticasone propionate has successfully been introduced. At present, it represents the only meaningful topical drug combination. Perhaps, it will be followed by others.
变应性鼻炎(AR)是由鼻腔内复杂的变应原驱动的黏膜炎症引起的。目前基于指南的变应性鼻炎治疗方法包括口服和鼻用抗组胺药、局部和全身用糖皮质激素、减充血剂、抗胆碱能药物、肥大细胞稳定剂、白三烯受体拮抗剂等。尽管有指南推荐,但大多数患者仍在使用多种疗法以试图控制症状。因此,显然需要更有效的变应性鼻炎治疗方法。最近,一种含有氮卓斯汀和丙酸氟替卡松的新型固定剂量复方制剂已成功推出。目前,它是唯一有意义的局部用药组合。也许,随后还会有其他组合出现。